Brain circuits in panic disorder

Biological Psychiatry

Volumn 44, Issue 12, 1998, Pages 1264-1276

  Coplan, Jeremy D ^a   Lydiard, R Bruce ^b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Anxiety; Neural circuits; Neurobiology; Neuroimaging; Panic disorder; Respiration

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AMYGDALOID NUCLEUS; ANIMAL MODEL; ANXIETY NEUROSIS; ARTICLE; COGNITION; FEAR; HUMAN; LIMBIC SYSTEM; LOCUS CERULEUS; MENTAL DISEASE; NEUROPSYCHIATRY; NEUROTRANSMISSION; NONHUMAN; PANIC; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0032535748     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00300-X     Document Type: Review

References (68)

1. Abelson J.L., Curtis G.C. Hypothalamic-pituitary-adrenal axis activity in panic disorder Prediction of long-term outcome by pretreatment cortisol levels . Am J Psychiatry. 153:1996;69-73.
2. Amaral D.G., Insausti R. Retrograde transport of D-[3H]-aspartate injected into the monkey amygdaloid complex. Exp Brain Res. 88:1992;375-388.
3. Aston-Jones G., Ennis M., Pieribone V.A., Nickell W.T., Shipley M.T. The brain nucleus locus ceruleus Restricted afferent control of a broad efferent network . Science. 234:1986;734-737.
4. Austin M.C., Rhodes J.L., Lewis D.A. Differential distribution of corticotropin-releasing hormone immunoreactive axons in monoaminergic nuclei of the human brainstem. Neuropsychopharmacology. 17:1997;326-341.
5. Azmitia E.C. The CNS serotonergic system Progression toward a collaborative organization . Meltzer H. Psychopharmacology The Third Generation of Progress . 1987;61-73 Raven Press, New York.
6. Azmitia EC, Whitaker PM (1995): Anatomy, cell biology, and plasticity of the serotonergic system: Neuropsychopharmacological implications for the actions of psychotropic drugs. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, pp 443-490.
7. Benkelfat C., Bradwejn J., Meyer E., et al. Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry. 152:1995;1180-1184.
8. Bourin M., Baker D.B., Bradwejn J. Neurobiology of panci disorder. J Psychosom Res. 14:1998;163-180.
9. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks A meta-analysis . Int Clin Psychopharmacol. 10:1993;45-49.
10. Bradwejn J., Koszycki D. Comparison of the panicogenic effect of cholecystokinin 30-33 and carbon dioxide in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 15:1991;237-239.
11. Bradwejn J., Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. Ann NY Acad Sci. 713:1994;273-282.
12. Bradwejn J., Koszycki Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry. 48:1991;603-610.
13. Charney D.S., Heninger G.R. Abnormal regulation of noradrenergic function in panic disorders Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder . Arch Gen Psychiatry. 43:1986;1042-1055.
14. Cohen Z., Bovento G., Lacombe P., Seylaz J., MacKenzie E.T., Hamel E. Cerebrovascular nerve fibers immunoreactive for tryptophan-5-hydroxylase in the rat Distribution, putative origin and comparison with sympathetic noradrenergic nerves . Brain Res. 598:1992;203-214.
15. Coplan J.D., Gorman J.M., Klein D.F. Serotonin-related function in panic disorder A critical overview . Neuropsychopharmacology. 6:1992;189-200.
16. Coplan J.D., Pine D., Papp L., et al. Uncoupling of the noradrenergic-hypothalamic-pituitary-adrenal axis in panic disorder patients. Neuropsychopharmacology. 13:1995;65-73.
17. Coplan J.D., Papp L.A., Pine D., et al. Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder. Arch Gen Psychiatry. 54:1997;643-648.
18. Coplan J.D., Goetz R., Klein D.F., et al. Plasma cortisol concentrations preceding lactate-induced panic. Psychological, biochemical, and physiological correlates. Arch Gen Psychiatry. 55:1998;130-136.
19. Dager S.R., Swann A.C. Advances in brain metabolism research Toward a moving picture of neural activity . Biol Psychiatry. 39:1996;231-233.
20. Deakin J.F.W., Graeff F.G. 5-HT and mechanisms of defence. J Psychopharmacol. 5:1991;305-315.
21. de Cristofaro M.T.R., Sessarego A., Pupi A., Faravelli C. Brain perfusion abnormalities in drug-naive lactate-sensitive panic patients A SPECT study . Biol Psychiatry. 33:1993;505-512.
22. Eriksson E., Westberg P., Alling C., Thuresson K., Modigh K. Cerebrospinal fluid levels of monoamine metabolites in panic disorder. Psychiatry Res. 39:1991;243-251.
23. Fossey M.D., Lydiard R.B., Ballenger J.C., Laraia M.T., Bissette G., Nemeroff C.B. Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry. 39:1996;703-707.
24. Goddard A.W., Charney D.S. Toward an integrated neurobiology of panic disorder. J Clin Psychiatry. 58:(suppl 2):1997;4-11.
25. Goddard A.W., Woods S.W., Sholomskas D.E., Goodman W.K., Charney D.S., Heninger G.R. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Research. 48:1993;119-133.
26. Gorman J.M., Liebowitz M.R., Fyer A.F., et al. A neuroanatomical hypothesis for panic disorder. Am J Psychiatry. 146:1989;148-161.
27. Graeff F.G. Brain defence systems and anxiety. Roth M., Burrows G.D., Noyes R. Handbook of Anxiety, vol 3. 1990;307-357 Elsevier Science Publishers, Amsterdam.
28. Gray J.A. The neuropsychological basis of anxiety. Last G.C., Hersen M. Handbook of Anxiety Disorder. 1988;10-40 Pergamon Press, New York.
29. Grove G., Coplan J.D., Hollander E. The neuroanatomy of 5-HT dysregulation and panic disorder. J Neuropsychiatry Clin Neurosci. 9:1997;198-207.
30. Gur R.C., Gur R.E., Resnick S.M., Skolnick B.E., Alavi A., Reivich M. The effect of anxiety on cortical cerebral blood flow and metabolism. J Cereb Blood Flow Metab. 7:1987;173-177.
31. Handley S.L. 5-hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther. 66:1995;103-148.
32. Hsiao J.K., Potter W.Z. Mechanisms of action of antipanic drugs. Ballenger J.C. Clinical Aspects of Panic Disorder. 1990;239-317 Alan R Liss, New York.
33. Johnson M.R., Lydiard R.B. The neurobiology of anxiety disorders. Psychiatr Clin North Am. 18:1995;681-725.
34. Jolkkonen J., Lepola U., Bissette G., Nemeroff C., Riekkinen P. CSF corticotropin-releasing factor is not affected in panic disorder. Biol Psychiatry. 33:1993;136-138.
35. Kaschka W., Feistel H., Ebert D. Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. J Psychiatr Res. 29:1995;427-434.
36. Kelly P.A., Ritchie I.M., McBean D.E., Sharkey J., Olverman H.J. Enhanced cerebrovascular responsiveness to hypercapnia following depletion of central serotonergic terminals. J Cereb Blood Flow Metab. 15:1995;706-713.
37. Klein D.F. Delineation of two drug-responsive syndromes. Psychopharmacologia. 53:1964;397-408.
38. Klein D.F. False suffocation alarms, spontaneous panics, and related conditions An integrative hypothesis . Arch Gen Psychiatry. 50:1993;306-318.
39. Kuikka J.T., Pitkanen A., Lepola U., et al. Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder. Nucl Med Commun. 16:1995;273-280.
40. LeDoux JE (current issue): Fear and the brain: Where have we been, and where are we going? Biol Psychiatry.
41. LeDoux J.E., Cicchetti P., Xagoraris A., Romanski L.M. The lateral amygdaloid nucleus Sensory interface of the amygdala in fear conditioning . J Neurosci. 10:1990;1062-1069.
42. Lee Y.J., Curtis G.C., Weg J.G., et al. Panic attacks induced by doxapram. Biol Psychiatry. 33:1993;295-297.
43. Lydiard R.B. Neuropeptides and anxiety Focus on cholecystokinin . Clin Chem. 40:1994;315-318.
44. Lydiard RB, Ballenger JC, Laraia MT, Fossey MD (1987): Noradrenergic dysregulaton in panic disorder: New CSF findings. Presented at the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 9-13.
45. Lydiard R.B., Ballenger J.C., Laraia M.T., et al. Effects of chronic alprazolam and imipramine treatment on catachoamine function in patients with agoraphobia with panic attacks or agoraphobia. Ballenger J.C. Clinical Aspects of Panic Disorder. 1990;239-249 Wiley-Liss, New York.
46. Lydiard R.B., Ballenger J.C., Laraia M.T., Fossey M.D., Beinfeld M. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry. 149:1992;691-693.
47. Lydiard R.B., Brawman-Mintzer O., Ballenger J.C. Recent developments in the psychopharmacology of anxiety disorders. J Consult Clin Psychol. 64:1996;660-668.
48. A-benzodiazepine receptor binding in panic disorder. Arch Gen Psychiatry. 55:1998;715-720.
49. Marazziti D., Rotondo A., Martini C., et al. Changes in peripheral benzodiazepine receptors in patients with panic disorder and obsessive-compulsive disorder. Neuropsychobiology. 29:1994;8-11.
50. McGaugh JL (1998): Emotional arousal, stress hormones, brain systems and lasting memory. Presented at the 18th Annual Meeting of the American Association of Anxiety Disorders symposium: "Brain Neurocircuitry of Anxiety and Fear: Implications for Clinical Research and Practice." Boston, Massachusetts, March 26.
51. Meltzer H.Y. Current Practices and Future Developments in the Psychopharmacology of Mental Disorders. 1991;83-88 Elsevier Science Publishers, Amsterdam.
52. Miranda F.J., Torregrosa G., Salom J.B., Campos V., Alabadi J.A., Alborch E. Inhibitory effect of GABA on cerebrovascular sympathetic neurotransmission. Brain Res. 492:1989;45-52.
53. Nashold BS Jr, Wilson WP, Slaughter G (1974): The midbrain and pain. In: Bonica JJ, editor. Advances in Neurology, vol 4: International Symposium on Pain. New York: Raven Press, pp 191-196.
54. Nordahl T.E., Semple W.E., Gross M., et al. Cerebral glucose metabolic differences in patients with panic disorder. Neuropsychopharmacology. 3:1990;261-273.
55. Nutt D., Lawson C. Panic attacks. A neurochemical overview of models and mechanisms. Br J Psychiatry. 160:1992;165-178.
56. Nyback H.V., Walters J.R., Agahjhanian G.K. Tricyclic antidepressants Effects on firing rate of brain noradrenergic neurons . Eur J Pharmacol. 32:1975;302-312.
57. Papp L.A., Klein D.F., Gorman J.M. Carbon dioxide hypersensitivity, hyperventilation, and panic disorder. Am J Psychiatry. 150:1993;1149-1157.
58. Papp L.A., Martinez J.M., Klein D.F., et al. Respiratory psychophysiology of panic disorder Three respiratory challenges in 98 subjects . Am J Psychiatry. 154:1997;1557-1565.
59. Price M.L., Curtis A.L., Kirby L.G., Valentino R.J., Lucki I. Effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology. 18:1998;492-502.
60. Redmond D.E. Jr. Studies of the nucleus locus coeruleus in monkeys and hypotheses for neuropsychopharmacology. Meltzer H.Y. Psychopharmacology The Third Generation of Progress . 1987;967-975 Raven Press, New York.
61. Reiman E.M. The application of positron emission tomography to the study of normal and pathologic emotions. J Clin Psychiatry. 58:(suppl 16):1997;4-12.
62. Reiman E.M., Raichle M.E., Robins E., et al. Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiatry. 46:1989;493-500.
63. Roy-Byrne P.P., Cowley D.S., Greenblatt D.J., Shader R.I., Hommer D. Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry. 47:1990;534-538.
64. Schlegel S., Steinert H., Bockisch A., Hahn K., Schloesser R., Benkert O. Decreased benzodiazepine receptor binding in panic disorder measured by Iomazenil-SPECT. A preliminary report. Eur Arch Psychiatry Clin Neurosci. 244:1994;49-51.
65. Sheline I.S., Bardgett M.E., Czernansky F.G. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG after treatment with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 17:1997;11-14.
66. Törk I, Hornung JP (1990): Raphe Nuclei and the Serotonergic System. The Human Nervous System in the Human Nervous system (edited by Paxinos G, Orlando, FL, pp. 1001-1022.
67. Wik G., Fredrikson M., Fischer H. Evidence of altered cerebral blood-flow relationships in acute phobia. Int J Neurosci. 91:1997;253-263.
68. Woods SW, Koster K, Krystal JK, et al (1988): Yohimbine alters regional cerebral blood flow in panic disorder [letter]. Lancet ii:678.